Anika Therapeutics (ANIK) Cost of Revenue (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cost of Revenue data on file, last reported at $10.6 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $10.6 million, down 7.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.1 million (up 6.15% YoY), and the FY2025 annual result was $49.0 million, up 11.62% from the prior year.
• Cost of Revenue fell to $10.6 million in Q1 2026 per ANIK's latest filing, from $11.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $17.5 million in Q3 2022 and troughed at -$8.7 million in Q4 2023.
• A 5-year average of $10.7 million and a median of $12.2 million in 2025 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue tumbled 137.1% in 2022, then surged 255.4% in 2024.
• A 5-year view of Cost of Revenue shows it stood at -$6.6 million in 2022, then tumbled by 32.15% to -$8.7 million in 2023, then surged by 255.4% to $13.5 million in 2024, then declined by 15.14% to $11.4 million in 2025, then retreated by 7.18% to $10.6 million in 2026.
• Business Quant data shows ANIK's Cost of Revenue at $10.6 million in Q1 2026, $11.4 million in Q4 2025, and $12.2 million in Q3 2025.